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Abstract
Background: The metabolism of amyloid precursor protein (APP) and β-amyloid (Aβ) is widely studied in Alzheimer's 
disease, where Aβ deposition and plaque development are essential components of the pathogenesis. However, the 
physiological role of amyloid in the adult nervous system remains largely unknown. We have previously found altered 
cerebral amyloid metabolism in other neuroinflammatory conditions. To further elucidate this, we investigated amyloid 
metabolism in patients with Lyme neuroborreliosis (LNB).
Methods: The first part of the study was a cross-sectional cohort study in 61 patients with acute facial palsy (19 with 
LNB and 42 with idiopathic facial paresis, Bell's palsy) and 22 healthy controls. CSF was analysed for the β-amyloid 
peptides Aβ38, Aβ40 and Aβ42, and the amyloid precursor protein (APP) isoforms α-sAPP and β-sAPP. CSF total-tau (T-
tau), phosphorylated tau (P-tau) and neurofilament protein (NFL) were measured to monitor neural cell damage. The 
second part of the study was a prospective cohort-study in 26 LNB patients undergoing consecutive lumbar punctures 
before and after antibiotic treatment to study time-dependent dynamics of the biomarkers.
Results: In the cross-sectional study, LNB patients had lower levels of CSF α-sAPP, β-sAPP and P-tau, and higher levels of 
CSF NFL than healthy controls and patients with Bell's palsy. In the prospective study, LNB patients had low levels of 
CSF α-sAPP, β-sAPP and P-tau at baseline, which all increased towards normal at follow-up.
Conclusions: Amyloid metabolism is altered in LNB. CSF levels of α-sAPP, β-sAPP and P-tau are decreased in acute 
infection and increase after treatment. In combination with earlier findings in multiple sclerosis, cerebral SLE and HIV 
with cerebral engagement, this points to an influence of neuroinflammation on amyloid metabolism.
Background
The trans-membranous protein amyloid precursor pro-
tein (APP) has been intensely studied in Alzheimer's dis-
ease (AD), since it is the source of β-amyloid (Aβ)
peptides, recognized as key-components in AD
pathophysiology [1]. Although ubiquitously expressed,
the physiological role of APP in the adult organism
remains largely unknown. APP may undergo non-amy-
loidogenic cleavage at the α-site, which inhibits formation
of Aβ and releases an extracellular soluble α-sAPP frag-
ment. Alternatively, APP is processed by combined cleav-
ages by β-secretase and γ-secretase, releasing Aβ and β-
sAPP. Aβ peptides vary in length due to variability in the
γ-secretase cleavage site. Although CSF levels of α-sAPP
and β-sAPP generally correlate tightly [2], it is not known
how these pathways are orchestrated in vivo. CSF levels of
α-sAPP and β-sAPP are reduced in MS and cerebral sys-
temic lupus erythematosus SLE [3], and even lower levels
are seen in HIV patients with cerebral engagement [4].
Lyme neuroborreliosis (LNB) is caused by a central ner-
vous system (CNS) infection by the tick-borne spirochete
Borrelia burgdorferi. LNB is often manifested by cranial
nerve engagement, and common clinical findings are
facial nerve palsy and radiculitic pain [5,6]. Common lab-
oratory findings are increased albumin ratio, indicating
impaired blood-brain barrier function, and CSF monocy-
tosis. In this study, we investigated CSF markers of amy-
loid metabolism and neural cell damage in LNB, to
elucidate the influence of neuroinflammation on amyloid
metabolism.
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The project contained two clinical studies. The first
was a cross-sectional study in patients with acute facial
palsy caused by either LNB or idiopathic Bell's palsy. The
second was a longitudinal prospective cohort-study,
where LNB patients were followed with successive lum-
bar punctures to investigate time-dependent biomarker
dynamics.
Methods
Study participants
We enrolled different study participants for the cross-
sectional study and the longitudinal study. Participants
included LNB patients, Bell's palsy patients and controls.
Diagnostic criteria for LNB were: I. Clinical symptoms
consistent with neuroborreliosis and alternative explana-
tions excluded; II Inflammatory CSF with mononuclear
cell count >5 × 106/l and erythrocytes <100 × 106/L; III.
One or more of the following: a) Intrathecal antibody
production against B burgdorferi sp. b) Antibodies against
B burgdorferi sp. in serum. c) Erythema migrans within
three months; and IV. One or more of the following: a)
CSF albumin >400 mg/L. b) Oligoclonal IgG and/or IgM-
synthesis on CSF protein electrophoresis. c) IgG index
(CSF/serum IgG ratio)/(CSF/serum albumin ratio) > .70.
Bell's palsy (idiopathic facial palsy) was defined as acute,
monosymptomatic, unilateral peripheral facial paresis of
unknown etiology. Bell's palsy patients were included as
non-infectious palsy controls.
In the cross-sectional part of the study we investigated
61 patients of whom 19 fulfilled criteria for LNB and 42
were classified as Bell's palsy. Twenty-two individuals for
whom CSF analysis was done because of headache or ver-
tigo, but infection and other diseases were excluded (CSF
albumin and cell count were normal), served as controls.
The longitudinal study included 26 LNB patients with
radiculitic pain and sensory disturbances. In addition, 3
patients had facial palsy, 3 had paraparesis, 1 had paresis
of the accessorius nerve, and 1 had a trigeminus paresis.
There was no overlap with the patients in the cross-sec-
tional study. Ten patients without any neurological disor-
ders, undergoing knee replacements, where CSF was
drawn before surgery (Table 1) served as controls in the
longitudinal study. These subjects are described in detail
elsewhere [7]. All LNB patients were given oral treatment
with doxycycline 200-400 mg daily for 10-14 days, which
is the standard treatment in Sweden [8]. CSF was drawn
before start of treatment and at follow-up. The median
duration between the samplings was 45 days (range 33-
61). All subjects gave informed consent to participate.
The study was approved by the ethics committee of Uni-
versity of Gothenburg.
Sampling
CSF samples were collected by lumbar puncture in the
L3/L4 or L4/L5 interspace. Four mL of CSF was collected
in a polypropylene tube and immediately transported to
the local laboratory for centrifugation at 2.000 g at +4°C
for 10 minutes. The supernatant was pipetted off, gently
mixed to avoid possible gradient effects, and aliquoted in
polypropylene tubes that were stored at -70°C pending
biochemical analyses, without being thawed and re-fro-
zen.
Biochemical procedures
All biochemical analyses were performed at the Clinical
Neurochemistry Laboratory in Mölndal, Sweden, by
experienced laboratory technicians who were blinded to
the clinical diagnoses and other clinical information.
Markers of amyloid metabolism
CSF levels of Aβ38, Aβ40 and Aβ42 were measured using
the MSD® Human/Rodent (4G8) Abeta Triplex Assay as
described by the manufacturer (Meso Scale Discovery,
MSD®, Gaithersburg, MD, USA). This assay employs the
4G8 antibody to capture Aβ and C-terminal specific anti-
bodies to specifically capture Aβ38, Aβ40 and Aβ42. All
isoforms are detected by SULFO-TAG™-labeled anti-4G8
detection antibody. CSF concentrations of α-sAPP and β-
sAPP were determined using the MSD® sAPPα/sAPPβ
Multiplex Assay as described by the manufacturer. This
assay employs the 6E10 antibody to capture α-sAPP and a
neoepitope-specific antibody to capture β-sAPP. Both
isoforms are detected by SULFO-TAG™-labeled anti-APP
antibody p2-1.
Markers of neural cell damage
The axonal damage marker CSF T-tau was measured
using a sandwich ELISA (INNOTEST® hTAU-Ag, Innoge-
netics, Ghent, Belgium) specifically constructed to mea-
sure all tau isoforms irrespectively of phosphorylation
status (T-tau), as previously described [9]. CSF concen-
trations of tau phosphorylated at threonine 181 (P-tau)
was measured using a sandwich ELISA (INNOTEST®
PHOSPHO-TAU(181P), Innogenetics), as previously
described [10]. CSF NFL, which is increased following
damage to large myelinated axon, was analyzed using an
ELISA, as previously described [11]. The detection limit
for the NFL ELISA was 125 ng/L.
Albumin
Quantitative determination of albumin in serum and CSF
was performed using the Behring Nephelometer Analyser
(Behringwerke AG, Marburg, Germany). The CSF/serum
albumin ratio was calculated as: CSF albumin (mg/l)/
serum-albumin (g/l).
Statistical analyses
All statistical calculations were performed using SPSS
15.0 (SPSS Inc, Chicago, USA). As the distribution of
quantitative measures was significantly skewed, statistical
tests involving these variables were conducted using theMattsson et al. BMC Neurology 2010, 10:51
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non-parametric Kuskal-Wallis test for comparisons of
multiple groups and the Mann-Whitney U test for pair-
wise comparisons between groups. Quantitative variables
are presented as median (range). The Spearman correla-
tion coefficient was used for analyses of correlation
between variable levels in different study groups. Statisti-
cal significance was determined at P < .05.
Role of the funding source
The sponsors of the study had no role in study design,
data collection, data analysis, data interpretation, or writ-
ing of the report. The corresponding author had full
access to all the data in the study and had final responsi-
bility for the decision to submit for publication.
Results
In the cross-sectional study all groups were comparable
in age. The only exception was that Bell's palsy patients
were slightly younger than the controls (P = .023, Table
1). LNB patients had longer history of neurological symp-
toms before the time of lumbar puncture than Bell's palsy
patients (Table 1).
In the longitudinal study, LNB patients were younger
than the controls (P = .031, Table 1). The median dura-
tion of neurologic symptoms was 7 days longer than in
the cross-sectional study (21 days compared with 28
days). At follow-up, all LNB patients had improved in
their clinical symptoms and their inflammatory reactions
had diminished, with decreased CSF monocytic cell
counts (Table 1).
Amyloid metabolism
In the cross-sectional study, LNB patients had lower α-
sAPP and β-sAPP than the other groups (Figure 1), but
there were no differences in Aβ38, Aβ40 or Aβ42 (Table
2). α-sAPP and β-sAPP correlated to most Aβ peptides in
Bell's palsy patients (R = .47-.60, P ≤ .002) and controls (R
= .42-.55, P < .05; the only exception was α-sAPP and
Aβ38 in controls, where there was a trend towards signif-
icance, R = .40, P = .065), but not in LNB patients (P >
.05).
In the longitudinal study, LNB patients had lower base-
line levels of α-sAPP and β-sAPP (Figure 2) and Aβ pep-
tides than controls (Table 3). α-sAPP and β-sAPP
increased after treatment (Figure 2), while Aβ levels were
unaffected (Table 3). Conversely to what was seen in the
cross-sectional study, α-sAPP and β-sAPP correlated to
all Aβ peptides in LNB in the longitudinal study (R = .71-
.98, P < .001), but not in controls (P > .05).
Table 1: Study participants and routine CSF analysisa
Group N M/F Age
years
Disease
durationb
CSF monocytes
×106/L
CSF albumin ratio CSF albumin (mg/l)
mean (range)
Cross-sectional study
Controls 22 9/13 44
(25-67)
-1
(1 - 34)
4.65
(2.7-10.5)
222
(83 - 411)
LNB with 
facial palsy
19 11/8 42
(8 - 72)
21 136
(14 - 534)
16.3c
(3.8-49.9)
861c
(166 - 2850)
Bell's palsy 42 18/24 36
(16-70)
52
(1 - 39)
4.7d
(2.3-11.5)
206d
(114 - 569)
Follow-up study
Controls 10 6/4 63
(51-70)
-M i s s i n g  d a t a 6 . 4
(4.7-10.1)
302
(192 - 579)
Baseline Follow-up Baseline Follow-up Baseline Follow-up
LNB 26 17/9 49
(12-74)
28 105
(14-590)
12
(2-21)
15c
(5.7-49.3)
6.1e
(4.7-13.6)
816c
(267-2180)
322e
(146-707)
CSF, cerebrospinal fluid; LNB, Lyme neuroborreliosis; adata presented as median (range), if not stated otherwise; bany neurologic symptom 
including radiculitic pain before study inclusion, presented as days (median); cP < .001 vs controls; dP < .001 vs LNB; eP < .001 vs LNB baseline.Mattsson et al. BMC Neurology 2010, 10:51
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Aβ38 correlated to Aβ40 (R = .91-.97, P < .001) and
Aβ42 (R = .74-.92, P < .001), and Aβ40 correlated to Aβ42
(R = .69-.93, P ≤ .001), in all groups. These correlations
were expected, since none of the subjects had any known
amyloid plaque pathology, which could have entrapped
Aβ40 and Aβ42 in the brain parenchyma. In the absence
of plaques, these Aβ peptides are likely to diffuse at simi-
lar rates to the CSF. α-sAPP and β-sAPP correlated in all
groups (R = .88-.95, P < .001), indicating that the path-
ways producing these peptides are tightly synchronized
in vivo.
Total-tau, Phospho-tau and NFL
LNB and Bell's palsy patients had similar T-tau levels in
the cross-sectional study, indicating that there was no sig-
nificant difference in the amount of cortical axonal dam-
age between the groups (Table 2). However, LNB patients
had lower P-tau and higher NFL, the latter indicating
damage to myelinated axons (Table 2). In the longitudinal
study, LNB patients had lower P-tau than controls (Table
3). T-tau and P-tau correlated in all groups (R = .84-.99, P
< .001).
Blood-brain barrier function
In acute disease stage, LNB patients had elevated albumin
ratio, reflecting blood-brain barrier dysfunction, which
improved after treatment (Table 1). In the cross-sectional
study, albumin ratio correlated to β-sAPP in controls (R =
.55, P = .018) and to NFL in LNB patients (R = .51, P =
.039). In the longitudinal study, albumin ratio correlated
inversely to α-sAPP and β-sAPP in LNB patients at base-
line (R = -.49, P = .027; R = -.49, P = .028). The correla-
tions seen in LNB could reflect that all these
measurements monitor the severity of pathology, rather
than a dependency on blood-brain barrier function for
sAPP and NFL.
Discussion
We found signs of altered brain amyloid metabolism in
LNB. CSF levels of the soluble APP-fragments α-sAPP
and β-sAPP were decreased in the acute stage of the dis-
ease, and increased following treatment with antibiotics.
Patients with Bell's palsy had no inflammatory activity in
CSF and higher CSF α-sAPP and β-sAPP concentrations
than LNB patients. These findings add to previous evi-
dence of altered amyloid metabolism in primary inflam-
matory CNS diseases such as MS, cerebral SLE and HIV
with cerebral engagement. In MS, α-sAPP and β-sAPP
levels were significantly lower in patients with ongoing or
Table 2: CSF biomarker levels in the cross-sectional studya
Group Aβ38
(ng/L)
Aβ40
(ng/L)
Aβ42
(ng/L)
T-tau
(ng/L)
P-tau
(ng/L)
NFLb
Controls 779
(323-1767)
6040
(3372-9885)
531
(240-992)
158
(74-553)
36
(20-99)
2/22
LNB 570
(270-2106)
5436
(3456-9465)
434
(198-978)
129
(75-335)
31
(22-71)
10/19d
Bell's palsy 694
(108-1615)
5819
(1316-9780)
440
(71-1010)
155
(75-420)
44c
(15-80)
6/42e
CSF, cerebrospinal fluid; LNB, Lyme neuroborreliosis; adata presented as median (range); bnumber of patients with CSF concentrations above 
the detection limit 125 ng/L; cP = .02 vs LNB; dP = .002 vs controls; eP = .002 vs LNB
Figure 1 CSF levels of α-sAPP and β-sAPP in controls, Bell's palsy 
patients and LNB patients. Horizontal lines indicate mean values. CSF 
α-sAPP (panel A) and β-sAPP (panel B) were reduced in LNB patients 
compared to controls and patients with Bell's palsy.Mattsson et al. BMC Neurology 2010, 10:51
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recent disease exacerbation compared to patients in sta-
ble remission [3]. In light of these findings, we suggest
that CSF levels of α-sAPP and β-sAPP may be generally
reduced in diseases with pronounced neuroinflamma-
tion. T his should be compared to what is seen in AD .
Although AD is primarily a neurodegenerative condition,
it also has strong inflammatory components [12]. The
dense core amyloid plaques in AD brain tissue are sur-
rounded by activated microglia [13]. However, although
these cells may phagocytose Aβ it is yet unknown pre-
cisely how the inflammatory activity affects amyloid
metabolism in AD. Net effects on sAPP proteins differ
from what is seen in MS, cerebral SLE and CNS infec-
tions, since AD patients have unaltered or even elevated
CSF levels of α-sAPP and β-sAPP [2,14,15]. Regarding
Bell's palsy, it is an important differential diagnosis to
LNB. Although the primary aim of our study was not to
assess the diagnostic performance of the amyloid mark-
ers, we think it is interesting to note the striking differ-
ences between facial palsy caused by LNB and Bell's palsy.
Although low α-sAPP and β-sAPP levels appear to be
consistent findings in diseases with pronounced neuroin-
flammation, the picture becomes more complex when we
turn to Aβ peptides. All subjects in the cross-sectional
study in the current project had similar Aβ, but in the
longitudinal study LNB patients had lower Aβ levels than
controls. Note that the LNB patients differed in neurolog-
ical symptoms between these two parts of the study.
Other studies have found decreased Aβ42 in MS, bacte-
rial meningitis and HIV with cerebral engagement [16]
but not in viral meningitis [3,17]. Thus, the etiology,
duration or severity of the neuroinflammation might
affect its influence on Aβ metabolism. In AD, CSF levels
of Aβ42 are decreased, which is often explained by accu-
mulation of Aβ42 in plaques [18]. However, low Aβ42 lev-
els may also be seen in Creutzfeld-Jakob's disease, where
the abundance of plaques is low [19]. Thus, other mecha-
nisms than plaque accumulation could contribute to low
CSF Aβ42 levels in neurodegenerative diseases.
In principle, reduced levels of CSF sAPP could be
caused by 1) decreased expression of APP, 2) decreased
processing of APP into sAPP, 3) decreased clearance of
sAPP into CSF, or 4) increased degradation of sAPP. Pres-
ently, it is not possible to draw definite conclusions on
Table 3: CSF biomarker levels in the follow-up studya
Group Aβ38
(ng/L)
Aβ40
(ng/L)
Aβ42
(ng/L)
T-tau
(ng/L)
P-tau
(ng/L)
Controls 891
(279-1715)
6676
(3450-9672)
672
(293-1193)
349
(171-552)
47
(23-69)
LNB baseline 561b
(254-1609)
4840c
(2726-8857)
378d
(211-997)
229e
(171-526)
30c
(16-60)
LNB follow-up 510f
(234-1562)
4310g
(2449-8690)
310h
(171-894)
235i
(171-532)
33j,k
(16-74)
CSF, cerebrospinal fluid; LNB, Lyme neuroborreliosis; adata presented as median (range); bP = .015 vs controls; cP = .006 vs controls; dP = .013 
vs controls; eP = .01 vs controls; fP = .021 vs controls; gP = .005 vs controls; hP = .004 vs controls; iP = .031 vs controls; jP = .041 vs controls; kP 
= .004 vs LNB baseline.
Figure 2 CSF levels of α-sAPP and β-sAPP in LNB patients with fol-
low-up and controls. Horizontal lines indicate mean values. CSF α-
sAPP (panel A) and β-sAPP (panel B) were reduced in LNB patients 
compared to controls at baseline, and increased at follow-up.Mattsson et al. BMC Neurology 2010, 10:51
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which of these mechanisms that operate in neuroinflam-
mation. In cases where no clear reductions in CSF Aβ
peptides are seen, such as facial palsy LNB, a decreased
APP expression is unlikely. Likewise, altered APP pro-
cessing with lower β-secretase activity would cause lower
levels of both β-sAPP and Aβ peptides. Regarding the
third possibility, decreased clearance of sAPP into CSF, it
is known that Aβ42 under certain conditions might be
trapped in interstitial drainage pathways [20]. It is not
known if this is also the case for sAPP. Finally, increased
degradation of sAPP in neuroinflammation remains a
vital possibility. Little definite data exist on the physiolog-
ical roles of sAPP, although α-sAPP has been attributed
with neuroprotective properties [21]. Particularly inter-
esting in the context of neural damage is a recently
described neurotoxic N-terminal APP-fragment, located
within the sAPP-sequence, capable of inducing axonal
degeneration through interaction with axonal DR6 recep-
tors [22]. Further research should be undertaken to
explore whether α-sAPP and β-sAPP share these axonal
degenerative properties, or if they are metabolised into
DR6-activating peptides in neuroinflammation.
In the follow-up part of the present study LNB patients
improved clinically after oral doxycycline, with dramatic
effects on the radiculitic pain and a slower recovery of
peripheral paresis. CSF analysis with decreased CSF
inflammation measured as number of monocytic cells
and normalization of the blood-brain barrier measured as
albumin ratio support the excellent therapeutic effect.
The LNB patients were younger than the controls, which
might affect the statistical analysis of some parameters.
However, in the study on MS referred to earlier, CSF lev-
els of α-sAPP and β-sAPP decreased in both patients and
controls during a 10 year follow-up [3]. Thus, it is
unlikely that the age difference explains the low baseline
levels of sAPP in young LNB patients compared to older
controls.
Regarding markers of neural damage and tau pathology,
we confirm earlier findings of increased CSF NFL in
some LNB patients, which indicates acute damage to
large myelinated axons [23]. White matter lesions have
also been described previously in LNB [24]. However, the
CSF NFL levels were low compared to other CNS dis-
eases such as herpes encephalitis [25]. NFL correlated to
albumin ratio, likely since both axons and the blood-brain
barrier are more affected in severe cases. For CSF T-tau,
considered a marker of damage to cortical axons [26], we
found no difference between LNB and Bell's palsy. This
suggests that the neural damage in LNB is not located to
cortical structures. T-tau levels were even lower in LNB
patients than in controls. Since CSF T-tau increases with
age, this could partly be explained by the age-difference
between LNB patients and controls [27]. CSF P-tau was
decreased in LNB patients, and increased after treatment
in the follow-up study. Thus, the acute neuroinflamma-
tion may have affected tau phosphorylation.
Conclusions
We report an association of cerebral amyloid metabolism
with LNB, with decreased CSF levels of soluble APP-frag-
ments in the acute disease stage. Besides possible impli-
cations for diagnosis of LNB, these findings strengthen
the case for a general involvement of amyloid in neuroin-
flammation and suggest that a physiological role of APP
could be to participate in inflammatory pathways. We
also confirm previous findings of elevated CSF NFL in
LNB, suggesting damage to myelinated axons. Further
research on amyloid metabolism in neuroinflammation
will likely shed more light on the functions of APP in the
adult human nervous system.
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